Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19222659 | ASSOCIATED FORMS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND LOCAL ANESTHETICS | May 2025 | October 2025 | Allow | 5 | 1 | 0 | No | No |
| 18899158 | POLYMERIC IODOPHOR COMPOSITIONS AND METHODS OF USE | September 2024 | March 2026 | Allow | 18 | 4 | 1 | No | No |
| 18659332 | COMBINATION TREATMENT FOR ANTIBIOTIC RESISTANT INFECTIONS | May 2024 | July 2025 | Abandon | 14 | 2 | 0 | No | No |
| 18602981 | PHARMACEUTICAL CAPSULES COMPRISING LUMATEPERONE MONO-TOSYLATE | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18431490 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | February 2024 | November 2025 | Allow | 21 | 1 | 0 | No | No |
| 18572144 | FREEZE-DRIED LOADED AEROGEL PARTICLES WITH BIOCIDAL PROPERTIES | December 2023 | April 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18524346 | OPHTHALMIC DRUG DELIVERY | November 2023 | August 2025 | Allow | 20 | 1 | 0 | No | No |
| 18512722 | COMBINATION TREATMENT FOR ANTIBIOTIC RESISTANT INFECTIONS | November 2023 | July 2024 | Allow | 8 | 2 | 0 | No | No |
| 18511751 | COMBINATION TREATMENT FOR ANTIBIOTIC RESISTANT INFECTIONS | November 2023 | November 2024 | Abandon | 12 | 0 | 0 | No | No |
| 18504345 | PHARMACEUTICAL CAPSULE COMPOSITIONS COMPRISING LUMATEPERONE MONO-TOSYLATE | November 2023 | May 2024 | Allow | 6 | 1 | 0 | No | No |
| 18385027 | THERAPEUTIC DETOXIFICATION COMPOSITIONS AND METHODS OF MAKING AND USING SAME | October 2023 | October 2025 | Allow | 23 | 2 | 1 | No | No |
| 18382654 | COSMETIC COMPOSITIONS AND METHODS | October 2023 | August 2025 | Allow | 22 | 2 | 0 | No | No |
| 18553334 | METHODS AND COMPOSITIONS FOR TREATING HYPERPIGMENTATION DISORDERS | September 2023 | March 2026 | Abandon | 30 | 1 | 0 | No | No |
| 18553403 | NANOVESICLES DERIVED FROM BACTERIA OF THE GENUS PARACOCCUS AND USE THEREOF | September 2023 | March 2026 | Abandon | 29 | 1 | 0 | No | No |
| 18478482 | METHODS OF TREATMENT COMPRISING ADMINISTERING LUMATEPERONE MONO-TOSYLATE CAPSULES | September 2023 | June 2025 | Allow | 21 | 2 | 0 | Yes | No |
| 18367869 | VAGINAL FILMS | September 2023 | July 2025 | Allow | 22 | 3 | 0 | No | No |
| 18236164 | Bicarbonate as a Potentiator for Antimicrobial Agents | August 2023 | March 2026 | Allow | 31 | 1 | 0 | Yes | No |
| 18449547 | PREPARATION OF OCCLUSIVE DRESSINGS | August 2023 | January 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18225377 | COMPOSITION FOR TREATING OR PREVENTING SKIN PIGMENTATION | July 2023 | June 2025 | Allow | 22 | 2 | 0 | No | No |
| 18331772 | COMPOSITION OF MATTER, SYSTEM, AND METHOD FOR ENHANCED MAGNESIUM UPTAKE, RETENTION, AND SYNERGISTIC ACTIONS | June 2023 | June 2024 | Allow | 12 | 2 | 0 | No | No |
| 18255949 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | June 2023 | December 2025 | Abandon | 30 | 1 | 1 | No | No |
| 18324449 | OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS | May 2023 | October 2023 | Allow | 5 | 1 | 1 | No | No |
| 18323474 | IMMEDIATE RELEASE ABUSE-DETERRENT GRANULATED DOSAGE FORMS | May 2023 | September 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18253535 | OXYGEN CAPSULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | May 2023 | July 2025 | Allow | 26 | 0 | 0 | Yes | No |
| 18037568 | RUXOLITINIB OR DEUTERATED RUXOLITINIB COMPOSITION AND USES THEREOF | May 2023 | January 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18141112 | COMPOSITION FOR THE TREATMENT OF REFRACTORY PAINFUL INTERVERTEBRAL DISC RELATED DISORDERS AND METHOD FOR DELIVERY THEREOF TO TREAT THERETO | April 2023 | December 2023 | Allow | 7 | 1 | 0 | No | No |
| 18139553 | Sulfate Salt Formulations For Colon Cleansing | April 2023 | December 2025 | Abandon | 32 | 1 | 0 | No | No |
| 18139434 | GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF | April 2023 | December 2024 | Allow | 20 | 1 | 1 | No | No |
| 18298991 | Artificial Vitreous Humor for the Investigation of Drugs and Drug Formulations | April 2023 | December 2025 | Allow | 32 | 2 | 1 | No | No |
| 18130595 | COSMETIC COMPOSITION COMPRISING CERAMIDES AND SPHINGOLIPID | April 2023 | October 2025 | Allow | 31 | 1 | 0 | No | No |
| 18192432 | COMBINATION TREATMENT FOR ANTIBIOTIC RESISTANT INFECTIONS | March 2023 | April 2025 | Abandon | 25 | 4 | 1 | No | No |
| 18184270 | ABUSE-DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE | March 2023 | January 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18109769 | PREPARATION OF OCCLUSIVE DRESSINGS | February 2023 | January 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18108940 | COMPOSITIONS AND METHODS FOR REMEDIATING CHEMICAL WARFARE AGENT EXPOSED SKIN | February 2023 | December 2023 | Allow | 10 | 2 | 0 | No | No |
| 18040780 | ANTI-AGING AND ANTIOXIDANT COSMETIC COMPOSITION CONTAINING BROCCOLI EXOSOMES AS ACTIVE INGREDIENT AND FUNCTIONAL COSMETICS COMPRISING SAME | February 2023 | October 2025 | Allow | 32 | 1 | 0 | No | No |
| 18040450 | OLEYLCYSTEINEAMIDE OR DERIVATIVES THEREOF AND THEIR USE IN THERAPY | February 2023 | January 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18159756 | HYDROGEL MEMBRANE FOR ADHESION PREVENTION | January 2023 | June 2025 | Allow | 29 | 2 | 0 | No | No |
| 18098512 | PREPARATION METHOD FOR AND USE METHOD OF COLLAGEN MICROFIBER HEMOSTATIC MATERIAL | January 2023 | December 2025 | Allow | 35 | 1 | 0 | No | No |
| 18098466 | BISMUTH-THIOLS AS ANTISEPTICS FOR EPITHELIAL TISSUES, ACUTE AND CHRONIC WOUNDS, BACTERIAL BIOFILMS AND OTHER INDICATIONS | January 2023 | November 2025 | Abandon | 34 | 1 | 0 | No | No |
| 18154695 | PHARMACEUTICAL SPRAY COMPOSITION COMPRISING A VITAMIN D ANALOGUE AND CORTICOSTEROID | January 2023 | March 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18150145 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | January 2023 | April 2024 | Abandon | 15 | 3 | 0 | Yes | No |
| 18013858 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COVID-19 COMPRISING NANO-SIZED GRAPHENE OXIDE COMPOSITE AND METHOD USING SAME | December 2022 | February 2026 | Allow | 38 | 2 | 0 | Yes | No |
| 18001834 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3 -YL]PYRIMIDIN-5-YL} CARBAMATE | December 2022 | January 2026 | Allow | 37 | 1 | 1 | No | No |
| 18009450 | COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICAL AGENTS | December 2022 | December 2025 | Allow | 36 | 1 | 0 | No | No |
| 17986828 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH OXIDATIVE STRESS | November 2022 | March 2025 | Abandon | 28 | 2 | 0 | No | No |
| 17985248 | BLOCKING A PATHOGEN FROM EXPRESSING A VIRULENCE FACTOR | November 2022 | September 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17983588 | METHOD FOR PRODUCING BIOMIMETIC NUTRIENT MIXTURE VIA BIOMIMICRY | November 2022 | February 2026 | Allow | 39 | 2 | 0 | No | No |
| 17983125 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | November 2022 | March 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17997884 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | November 2022 | December 2025 | Allow | 37 | 1 | 0 | No | No |
| 17973640 | NANOPARTICLES TO PROMOTE WOUND HEALING AND ANTIMICROBIAL INFECTION CONTROL | October 2022 | February 2026 | Allow | 39 | 5 | 0 | Yes | No |
| 17973769 | THERAPEUTIC ARTICLE OF MANUFACTURE WITH NANOPARTICLES TO PROMOTE WOUND HEALING AND/OR ANTIMICROBIAL INFECTION CONTROL | October 2022 | January 2026 | Allow | 39 | 1 | 1 | No | No |
| 17920722 | NEW USES | October 2022 | December 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17919391 | MICROEMULSION COMPOSITION AND COSMETIC CONTAINING THE SAME | October 2022 | December 2025 | Allow | 38 | 1 | 0 | No | No |
| 17965859 | INHALABLE RAPAMYCIN FORMULATION FOR THE TREATMENT OF PULMONARY HYPERTENSION | October 2022 | November 2025 | Allow | 37 | 3 | 0 | No | No |
| 17958709 | Nanoparticles and Nanogel Drug Compositions for Treatment of Age-related Macular Degeneration | October 2022 | July 2025 | Allow | 34 | 2 | 1 | No | No |
| 17995167 | METHOD FOR PREVENTING OR TREATING LUNG INFECTION AND LUNG INFLAMMATION | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17948968 | INGESTIBLE MEDICAL DELIVERY DEVICES | September 2022 | January 2025 | Abandon | 27 | 2 | 0 | No | No |
| 17898318 | HYPOTONIC HYDROGEL FORMULATIONS FOR ENHANCED TRANSPORT OF ACTIVE AGENTS AT MUCOSAL SURFACES | August 2022 | August 2025 | Abandon | 36 | 2 | 0 | No | No |
| 17820325 | COMPOSITION OF MATTER, SYSTEM, AND METHOD FOR ENHANCED MAGNESIUM UPTAKE, RETENTION, AND SYNERGISTIC ACTIONS | August 2022 | March 2023 | Allow | 7 | 1 | 0 | No | No |
| 17885065 | COSMETIC COMPOSITIONS | August 2022 | February 2024 | Allow | 18 | 2 | 0 | No | No |
| 17869614 | Porcine Collagen Compositions and Methods of Use Thereof | July 2022 | August 2025 | Allow | 37 | 3 | 0 | Yes | No |
| 17812832 | NANOPARTICLE DELIVERY SYSTEMS | July 2022 | June 2025 | Abandon | 35 | 2 | 0 | No | No |
| 17861711 | Misoprostol Dispersible Tablet | July 2022 | February 2024 | Allow | 19 | 2 | 0 | No | No |
| 17758452 | SOLID STATE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR PRODUCING AND USING SAME | July 2022 | October 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17857442 | STABILIZED TACROLIMUS COMPOSITION | July 2022 | May 2025 | Allow | 34 | 3 | 0 | No | No |
| 17790180 | Chitosan-Based Beads, and Preparation, Compositions and Uses Thereof | June 2022 | December 2025 | Allow | 42 | 1 | 1 | No | No |
| 17853650 | Topical Compositions For Treating Skin Ailments | June 2022 | November 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17758175 | TOPICAL COMPOSITION COMPRISING TOFACITINIB AND FINGOLIMOD | June 2022 | November 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17849425 | OPHTHALMIC DRUG DELIVERY | June 2022 | October 2023 | Allow | 15 | 1 | 0 | No | No |
| 17844949 | COMPOSITION COMPRISING COMPOUND OF THIOPYRIDINONE TYPE AND POLYGLYCERYL-BASED EMULSIFIERS | June 2022 | September 2025 | Allow | 39 | 3 | 0 | No | No |
| 17838064 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | June 2022 | September 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17832918 | SCALP PROTECTION COMPOSITION | June 2022 | April 2024 | Allow | 23 | 1 | 0 | No | No |
| 17826069 | DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHOD | May 2022 | November 2022 | Allow | 6 | 1 | 0 | No | No |
| 17826082 | DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHOD | May 2022 | November 2022 | Allow | 6 | 1 | 0 | No | No |
| 17826042 | DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHOD | May 2022 | December 2022 | Allow | 7 | 1 | 0 | No | No |
| 17826034 | DEEP TOPICAL SYSTEMIC NITRIC OXIDE THERAPY APPARATUS AND METHOD | May 2022 | November 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17824516 | NOVEL POVIDONE-IODINE PHARMACEUTICAL PREPARATION AND USES THEREOF | May 2022 | November 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17739174 | POWDERIZED CANNABIS AND USES THEREOF | May 2022 | January 2026 | Allow | 45 | 2 | 0 | Yes | No |
| 17717532 | TOPICAL COMPOSITIONS COMPRISING DIAMINOOXIDASE FOR THE TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH HIGH HISTAMINE LEVELS WHICH INVOLVE AN INCREASE IN PAIN | April 2022 | October 2025 | Allow | 42 | 2 | 0 | No | Yes |
| 17715068 | PREBIOTIC AND PROBIOTIC COOKIE PREPARATION | April 2022 | July 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17714465 | Wound-Care Composition and Method of Use | April 2022 | December 2023 | Allow | 20 | 1 | 0 | No | No |
| 17702608 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS | March 2022 | November 2025 | Allow | 44 | 3 | 0 | Yes | No |
| 17760834 | Method of Improving Reproductive Ability | March 2022 | February 2026 | Allow | 47 | 3 | 0 | Yes | No |
| 17691989 | PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOF | March 2022 | March 2023 | Allow | 12 | 1 | 0 | No | No |
| 17687364 | SELF-FUELED PARTICLES FOR PROPULSION THROUGH FLOWING AQUEOUS FLUIDS | March 2022 | October 2024 | Allow | 32 | 2 | 0 | No | No |
| 17803148 | PERFORMANCE ENHANCEMENT DELIVERY SYSTEM | March 2022 | January 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17674146 | MICRONUTIRENT AND PLANT EXTRACT COMPOSITION AND METHOD OF IMRPOVING BONE HEALTH | February 2022 | August 2022 | Allow | 5 | 1 | 0 | No | No |
| 17673651 | BIOIMPLANT WITH EVANESCENT COATING FILM | February 2022 | February 2024 | Allow | 24 | 2 | 0 | Yes | No |
| 17589838 | PHARMACEUTICAL PREPARATIONS AND METHODS TO MANAGE WEIGHT AND TO MODULATE THE GUT MICROBIOTA | January 2022 | July 2024 | Abandon | 30 | 2 | 0 | Yes | No |
| 17584691 | Dedifferentiated cell extract of Bletilla and method for whitening, anti-oxidation and anti-wrinkling applying the same, and cosmetic comprising the same | January 2022 | March 2025 | Allow | 37 | 3 | 0 | No | No |
| 17582516 | METHODS OF TREATMENT USING PHARMACEUTICAL CAPSULE COMPOSITIONS COMPRISING LUMATEPERONE MONO-TOSYLATE | January 2022 | July 2023 | Allow | 18 | 1 | 0 | No | No |
| 17569715 | COSMETIC COMPOSITIONS AND METHODS | January 2022 | July 2023 | Allow | 18 | 1 | 0 | No | No |
| 17647149 | METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER | January 2022 | September 2023 | Allow | 21 | 1 | 0 | No | No |
| 17565348 | METHODS AND COMPOSITIONS OF AQUEOUS HYPOBROMOUS ACID FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY CONDITIONS | December 2021 | March 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17561198 | COMPOSITIONS AND METHODS FOR TREATING DISEASES OF THE NAIL | December 2021 | September 2023 | Allow | 20 | 1 | 0 | No | No |
| 17559158 | IMMEDIATE RELEASE ABUSE-DETERRENT GRANULATED DOSAGE FORMS | December 2021 | August 2022 | Allow | 8 | 1 | 0 | No | No |
| 17558179 | TRANSDERMAL PATCHES FOR HANGOVER MINIMIZATION AND/OR RECOCERY, AND/OR SLEEP IMPROVEMENT | December 2021 | September 2024 | Allow | 33 | 2 | 0 | No | No |
| 17549975 | Cosmetic Compositions Comprising Sucrose Esters And Solvents | December 2021 | October 2024 | Allow | 34 | 4 | 0 | No | No |
| 17548931 | ABUSE-DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE | December 2021 | September 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17546645 | POLYMER SYSTEM FOR OPHTHALMIC DRUG DELIVERY | December 2021 | May 2025 | Allow | 41 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STEVENS, MARK V.
With a 22.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner STEVENS, MARK V works in Art Unit 1613 and has examined 771 patent applications in our dataset. With an allowance rate of 65.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 26 months.
Examiner STEVENS, MARK V's allowance rate of 65.5% places them in the 26% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by STEVENS, MARK V receive 2.39 office actions before reaching final disposition. This places the examiner in the 69% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by STEVENS, MARK V is 26 months. This places the examiner in the 75% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +47.9% benefit to allowance rate for applications examined by STEVENS, MARK V. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.9% of applications are subsequently allowed. This success rate is in the 30% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 47.3% of cases where such amendments are filed. This entry rate is in the 72% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 75.7% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 82.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 65.8% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 50% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.6% of allowed cases (in the 76% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.